ZIOPHARM Oncology Inc (ZIOP) Shares are Up 6.64%

ZIOPHARM Oncology Inc (ZIOP) : Traders are bullish on ZIOPHARM Oncology Inc (ZIOP) as it has outperformed the S&P 500 by a wide margin of 7.87% in the past 4 weeks. The bullishness in the stock continues even in the near-term as the stock has returned an impressive 6.58%, relative to the S&P 500. The stock has continued its bullish performance both in the near-term and the medium-term, as the stock is up 6.64% in the last 1 week, and is up 8.98% in the past 4 weeks. Buying continues as the stock moves higher, suggesting a strong appetite for the stock.

The stock has recorded a 20-day Moving Average of 11.67% and the 50-Day Moving Average is 3.62%. ZIOPHARM Oncology Inc (NASDAQ:ZIOP): stock turned positive on Friday. Though the stock opened at $5.25, the bulls momentum made the stock top out at $5.48 level for the day. The stock recorded a low of $5.18 and closed the trading day at $5.46, in the green by 4.80%. The total traded volume for the day was 1,799,132. The stock had closed at $5.21 in the previous days trading.


The company Insiders own 11.5% of ZIOPHARM Oncology Inc shares according to the proxy statements. Institutional Investors own 42.38% of ZIOPHARM Oncology Inc shares. Also, Equity analysts at the Brokerage firm Wells Fargo upgrades its rating on ZIOPHARM Oncology Inc (NASDAQ:ZIOP). The rating major has initiated the coverage with market perform rating on the shares. Earlier, the shares were rated a Underperform by the brokerage firm. The rating by the firm was issued on August 10, 2016.

ZIOPHARM Oncology, Inc. is a biopharmaceutical company. The Company is engaged in the acquisition, development and commercialization of a portfolio of cancer therapies through synthetic biology. The Companys pipeline includes a number of cell-based therapeutics in both clinical and preclinical testing which are focused on hematologic and solid tumor malignancies. The Companys clinical stage product candidate, Ad-RTS-IL-12 is used with the oral activator veledimex being developed for the treatment of oncology. Ad-RTS-IL-12 in combination with veledimex uses the synthetic biology platform (gene-delivery system) to produce Interleukin-12, or IL-12, a potent, naturally occurring anti-cancer protein. The Company has completed two Phase II studies evaluating Ad-RTS-IL-12 in combination with veledimex, for the treatment of metastatic melanoma, and for the treatment of metastatic breast cancer. The Company is also developing CAR-T Cells (Cytokine products).

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *